Nearly three decades later, drug makers have developed six approved small interfering RNA (siRNA) therapeutics in the ...

Orna Therapeutics, part of a buzzy cohort of biotech companies established in the wake of the Covid pandemic, has cut more ...

Barclays analyst Gena Wang maintained a Buy rating on Avidity Biosciences (RNA – Research Report) today and set a price target of $63.00.

Compared to DNA sequencing alone, concurrent DNA and RNA sequencing revealed more clinically actionable variants in NSCLC.

The firm has made significant strides in its RNA editing and RNA interference programs, which are attracting positive attention and positioning the company for differentiation in the treatment of ...

On October 16, a biotechnology company in Massachusetts in the U.S. named Wave Life Sciences made headlines for becoming the ...

Texas A&M AgriLife researchers uncovered a promising target for controlling gene expression and other cellular processes, ...

An RNA-editing gene therapy has been developed that switches off the key driver of common eye conditions affecting diabetics ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Researchers have identified unique RNA structures called G-quadruplexes (G4s) that promote harmful α-synuclein protein ...

Researchers at the Department of Cell and Molecular Biology, Karolinska Institutet have made a major discovery in how human ...